Trade Mark Journal No.2026/033 14 August 2026
WO0000001930460 (5)
Office of origin: United States of America
Date of International Registration:8 April 2026
Date of designation in the UK:
8 April 2026

International priority date claimed: 23 October 2025
(United States of America)
(99458830)
- Class 5
- Antibodies for therapeutic purposes; pharmaceutical preparations for the treatment of cancer, myeloproliferative disorders, and hematological disorders.
Damora Therapeutics, Inc.
Representative: Nicole Kinsley FOLEY HOAG LLP, 155 Seaport Blvd., Boston MA 02210, UNITED STATES OF AMERICA